$DNTH

Analysts made several rating changes: Bernstein upgraded Ormat (ORA) to Market Perform, Morgan Stanley upgraded Shell (SHEL) to Overweight with a $101.30 target, Barclays upgraded W.P. Carey (WPC) to Equal Weight, Baird upgraded Sonida Senior Living (SNDA) to Outperform with a $43 target, and Piper Sandler upgraded Simmons First National (SFNC) to Overweight with a $27.50 target. Canaccord downgraded UiPath (PATH) to Hold with a $17 target, Craig-Hallum downgraded Ambarella (AMBA) to Hold with a

Analysts made several calls: Goldman Sachs reiterated Tesla as neutral, citing Cybercab's cost benefits. Bernstein kept Apple as outperform, noting market share gains. Baird upgraded Sonida Senior Living to outperform. Morgan Stanley upgraded Shell to overweight, expecting acceleration. Piper Sandler upgraded Simmons First National to overweight. Goldman upgraded Vodafone to buy. B. Riley initiated Infleqtion as buy. William Blair kept Nvidia as outperform, approving its Hugging Face acquisition

Randhawa Simrat (EVP, Head of R&D) sold 23,124 shares of Dianthus Therapeutics, Inc. /DE/ (DNTH) at an average of $106.41 ($105.19–$106.74, $2.46M total) across 3 trades on 2026-09-01 under a Rule 10b5-1 trading plan.

McGeorge Anne sold 7,750 shares of Dianthus Therapeutics, Inc. /DE/ (DNTH) at an average of $109.01 ($107.58–$111.41, $0.84M total) across 5 trades on 2026-08-10 under a Rule 10b5-1 trading plan.

Veness Adam M (SVP, General Counsel and Sec.) sold 20,000 shares of Dianthus Therapeutics, Inc. /DE/ (DNTH) at an average of $110.44 ($110.38–$111.18, $2.21M total) across 3 trades over 2026-08-07 to 2026-08-10 under a Rule 10b5-1 trading plan.

Dianthus Therapeutics (NasdaqCM:DNTH) reported Q2 2026 results with a wider net loss of $50.22 million and basic loss per share of $0.90, plus a $91.05 million net loss over six months. The company also introduced DNTH312, a bifunctional fusion protein targeting aC1s and BAFF/APRIL, and cited upcoming clinical catalysts including CAPTIVATE CIDP and EMERGE gMG.

Garcia Marino (CEO AND PRESIDENT) sold 166,000 shares of Dianthus Therapeutics, Inc. /DE/ (DNTH) at an average of $108.11 ($107.49–$110.76, $17.95M total) across 7 trades on 2026-08-07 under a Rule 10b5-1 trading plan.

Dianthus Therapeutics, Inc. /DE/ (DNTH) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 DIANTHUS THERAPEUTICS HIGHLIGHTS RECENT BUSINESS ACHIEVEMENTS AND REPORTS Q2 2026 FINANCIAL RESULTS Advancing a neuromuscular franchise with claseprubart, a highly potent investigational classical pathway inhibitor, with best-in-disease potential across generalized M

Savitz Ryan (EVP, CFO & CBO) sold 31,249 shares of Dianthus Therapeutics, Inc. /DE/ (DNTH) at an average of $101.03 ($100.22–$101.97, $3.16M total) across 3 trades on 2026-07-09 under a Rule 10b5-1 trading plan.

Dianthus Therapeutics (Nasdaq: DNTH) said it granted inducement equity awards on July 1, 2026 to five newly hired non-executive employees. The grants are non-qualified stock options for 58,000 shares, with a 10-year term and $90.21 exercise price; 25% vest after one year and the rest monthly over 36 months, per Nasdaq Rule 5635(c)(4).